Subscribe to Search results

In response to the media response on AIDS fears prompting recall of blood products Christopher Bishop said that Armour should treat media articles with the contempt they deserved and that they could not make a statement on reviewing the current heat process because they couldn't defend existing treatment and immediately introduce a new one.

Published on:

In a memo Christopher Bishop advised colleagues on responses to be used with regards to queries about them reviewing their heat treatment procedure and said they had a considerable quantity of existing material and they wouldn't want people to hold off ordering until the new product came through.

Published on:

In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat-treated product Robert Christie said Dr Harris had reported the findings in broad outline to the DHSS and promised to supply more information following a written report from Dr Hill. Robert Christie said he agreed that the incident should be reported to the DHSS and a publication describing Dr Hill's experience prepared.

Published on:

In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat treated product Robert Christie said Dr Harris had reported the findings in broad outline to DHSS and promised to supply more information following a written report from Dr Hill

Published on:

Dr Jeffreys Chief Medical Officer said further to the call with Dr Rotblatt they would need to visit the DHSS the next day before the weekend and that Armour would probably be "no doubt looking at voluntarily withdrawing the product on Monday".

Published on:

Armour's Factorate was removed from the market and two of its product licenses relinquished following consultation with the DHSS after two seroconversion cases of AIDS from heat treated Factorate.

Published on:

In a letter to Dr Rotblat, Dr Christie reported the second case of seroconversion following the use of heat-treated Armour Factorate.

Published on:

Dr Harris in a letter to Dr Colvin stated that each donation was now screened for HTLV-3 but that they recognised old material may be in centres and any decision to give patients information about this potentially distressing information rested with Dr Colvin as the unit director.

Published on:

The "Morbidity and Mortality Weekly Report" stated that the Medical and Scientific Advisory Council of the National Hemophilia Foundation recently issued revised recommendations for haemophilia therapy which included that the use of non-heat-treated factor concentrates should be limited.

Published on:

The "Morbidity and Mortality Weekly Report" included figures from Cutter which showed that their heat treatment process had inactivated HTLV-3 virus to a degree that the virus was undetectable after 24 hours of heat treatment.

Published on:

The Medical and Scientific Advisory Council of the US National Hemophilia Foundation endorsed the use of heat-treated products. The CDC endorsed the use of heat treatment. It carried out the viral inactivation studies on infectious particles in cooperation with Cutter Laboratories.

Published on:

Gilbert C et al published an article in "The Lancet" describing a case of seroconversion of AIDS in a person with mild haemophilia after administration of high doses of heat-treated Factor 8 concentrate.

Published on:

An article by Robert J Gerety and Lewellys F Barker described viral inactivation as one of the measures of interest since 1975 undertaken with hopes of increasing safety of haemophiliacs from HBV.

Published on:

A paper discussed Cutter continuing to carry out studies in the hope of finding ways in which Konyne product may be rendered non-infective.

Published on:

Horowitz et al discussed their viral inactivation study in this paper which was later put into production by the New York Blood Centre.

Published on:

A memo from Linda Frith showed the total volume of returned regular material and total sales of Koate, and that for a short period of time Cutter would take a share of the NHS Factor 8 market.

Published on:

A letter from Jack Wood at Cutter stated that Cutter felt it was prudent to no longer effect sales of non-heat-treated product for use in the UK following dramatic changes in the UK regarding heat-treated Factor 8 products.

Published on:

A memo from Jack Wood stated that for inventory which could not be reallocated by Cutter US they were to seek a one year extension from NIBS to allow them to relabel and sell over the coming year into markets not yet converted to heat-treated Factor 8 products.

Published on:

In a memo on figures of Cutte's products it showed that a small short-dated batch mentioned last month had now been sold and several other contacts had shown an interest in other batches and the material had been offered for sale.

Published on:

An internal memo described the outcome of a meeting where Dr Savidge presented results of his profilate HT trials and that the results provided evidence to support Alpha's claim that Profilate HT was free from non-A non-B Hepatitis.

Published on: